1. Distinguish risk factors and goals of therapy for patients with chronic obstructive pulmonary disease (COPD).
2. Assess patients with COPD and classify their risk stratification into A, B, or E categories.
3. Apply knowledge of nonpharmacologic techniques for COPD when educating patients.
4. Develop an appropriate pharmacologic regimen for patients with chronic stable COPD (initial and follow-up therapy).
5. Evaluate strategies to improve patient access to COPD medications and streamline regimens.
6. Discover new therapies on the horizon for patients with COPD.

1. Distinguish the most likely asthma phenotype based on symptoms, patient characteristics, and laboratory values.
2. Classify asthma severity based on current symptoms and future risk of asthma exacerbations.
3. Evaluate individual patient characteristics when choosing an appropriate inhaled drug delivery device.
4. Develop an appropriate pharmacotherapy treatment plan for a patient with newly diagnosed asthma, symptoms of worsening
asthma, and difficult-to-treat asthma.

1. Classify an upper respiratory tract infection (URTI) given an adult patient’s signs, symptoms, risk factors, medical history,
and laboratory results.
2. Design treatment plans, including nonpharmacologic therapy, nonprescription medications, and pharmacotherapy, for adult
patients with a URTI.
3. Evaluate the evidence, clinical appropriateness, and safety of complementary and integrative therapies to prevent or treat a
URTI.
4. Given a study assessing a URTI, evaluate the research design and biostatistical methods.

1. Evaluate a patient’s risk of acquiring HIV and determine whether the patient is a candidate for preexposure prophylaxis
(PrEP) initiation.
2. Design a patient-centered treatment plan for HIV PrEP.
3. Distinguish patients who are candidates for doxycycline postexposure prophylaxis (doxy PEP) and provide patient-centered
counseling.
4. Assess methods by which pharmacists can expand and enhance HIV prevention initiatives.

1. Analyze the epidemiology of Long coronavirus disease 2019 (Long COVID).
2. Develop an understanding of how Long COVID is diagnosed.
3. Assess risk factors for Long COVID.
4. Demonstrate an understanding of the complexities surrounding the clinical manifestations of Long COVID.
5. Synthesize the current research on the potential mechanisms of Long COVID.
6. Assess the current knowledge on the prevention and treatment of Long COVID.
7. Assess gaps in current knowledge related to pathogenesis, diagnosis, and management of Long COVID.

1. Evaluate the current epidemiologic trends in prescription opioid misuse and illicit opioid use, including overdose and use
disorders.
2. Distinguish opioid use neurobiology with initial use and with prolonged use as it applies to the development of an opioid use
disorder (OUD) and return to use risk.
3. Apply universal screening techniques for substance use disorders and compare the screening tools available.
4. Develop an individualized, patient-centered treatment plan for OUD by evaluating appropriate medication and psychosocial
intervention options.
5. Classify the clinical pharmacology, efficacy, and safety of methadone, buprenorphine, and naltrexone in treating OUD.
6. Distinguish unique differences in treating adolescents, young adults, pregnant and postpartum patients, and individuals
with co-occurring use disorders with medications for OUD.
7. Develop a comprehensive harm reduction plan for an individual with OUD considering their unique recovery journey.
8. Classify recent changes to legislation and regulation of OUD treatment.

1. Distinguish between seizure types, epilepsy types, and epilepsy syndromes.
2. Evaluate current pharmacotherapy options for the treatment of epilepsy.
3. Evaluate current non-pharmacotherapy options for the treatment of epilepsy.
4. Analyze safety considerations for antiseizure medications.
5. Develop epilepsy-related patient-specific patient education.

1. Classify type of migraine based on clinical presentation.
2. Assess the appropriateness of acute and preventive therapies for migraine.
3. Develop a comprehensive migraine medication plan given a patient case.
4. Develop nonpharmacologic recommendations for migraine.
5. Evaluate migraine-specific medication treatments for potential place in migraine therapy.

1. Distinguish between symptoms of depressive and anxiety disorders.
2. Develop a treatment plan for a patient with major depressive disorder or anxiety disorders.
3. Evaluate a depression or anxiety treatment regimen for efficacy and safety.
4. Devise a treatment plan using recently approved medications for the treatment of major depressive disorder.

1. Classify the signs and symptoms of the three phases of bipolar disorder (hypomania, mania, and depression).
2. Distinguish the efficacy and safety of pharmacotherapeutic treatment options for the treatment of bipolar disorder.
3. Distinguish appropriate monitoring parameters for bipolar disorder treatment.
4. Given a patient case, assess an appropriate medication regimen for the treatment of bipolar disorder.